Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Hypertriglyceridemia: early-phase trial registry
3 of 27 indexed Hypertriglyceridemia trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #598 of 28,707 conditions by registered trial count.
27 US clinical trials · 3 currently recruiting · #598 of 28,707 conditions by registered trial count
Hypertriglyceridemia: 27 US clinical trials tracked, 3 recruiting.
Hypertriglyceridemia is the subject of 27 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 6 are in Phase 3-4 (later-stage) and 13 in Phase 1-2 (earlier-stage). The most active sponsor is AstraZeneca, running 4 of these trials.
Enrollment posture brief
Registry condition hypertriglyceridemia
OPEN 3 | RECR 11% | LATE 6 | EARLY 13 | RANK #598 | SPON 4
Volume-matched condition peers
Nearest open-share peer: Acute Heart Failure (11% recruiting · 9 trials)
Hypertriglyceridemia lists 3 open slots (11% of 27 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Hypertriglyceridemia on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Hypertriglyceridemia is recruiting below its size-band peers.
3 of 27 indexed trials (11.1%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Hypertriglyceridemia trials is spread across many organizations.
AstraZeneca accounts for 4 of 27 trials (14.8%). 20 distinct sponsors appear on at least one study for this condition label.
-
Most Hypertriglyceridemia trials plan to enrol fewer than 100 people.
Median target enrolment is 52 among the 26 trials that report a genuine target (sentinel values excluded). 17 of those (65.4%) plan for fewer than 100 participants.
-
Hypertriglyceridemia research is mostly interventional.
25 interventional and 2 observational studies make up this index (92.6% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
27 total, page 1 of 1
Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia
Arrowhead Pharmaceuticals
NCT06822790
Differential Thrombogenesis by EPA and DHA Mediated by HDL
The Miriam Hospital
NCT06494488
A Mechanistic Study of MAR001 in Adults With Elevated Triglycerides and Remnant Cholesterol
Marea Therapeutics
NCT07199309
Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia
Arrowhead Pharmaceuticals
NCT06347133
Study of MAR001 in Adults With Elevated Triglycerides and Remnant Cholesterol
Marea Therapeutics
NCT07028749
Study of RN0361in Adult Healthy Subjects and Adult Hypertriglyceridemic Subjects
Ikaria Bioscience Pty
NCT06471543
MN-001 in Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus, and Hypertriglyceridemia
MediciNova
NCT05464784
[E]PANOVA Combined With a [S]TATIN in [P]ATIENTS With HYPERT[R]IGLYCER[I]DEMIA to Reduce Non-HDL CHOLES[T]EROL
AstraZeneca
NCT01408303
A Study Comparing The Efficacy & Safety Of Torcetrapib/Atorvastatin And Atorvastatin In Subjects With High Triglycerides
Pfizer
NCT00134498
Effects of Amino Acids on Regional Lipid Metabolism
University of Arkansas
NCT01150188
Study to Evaluate the 2-Way Interaction Between Multiple Doses of Epanova™ and a Single Dose of Rosuvastatin (Crestor®)
AstraZeneca
NCT02859129
Effects of Omega-3 Fatty Acids on Markers of Inflammation
Stanford University
NCT01129050
Pilot Study To Assess CAT-2003 in Patients With Hyperlipidemia
Catabasis Pharmaceuticals
NCT01912560
Interaction of Epanova on Warfarin Pharmacokinetic and Anticoagulant Activity and Comparison of the Effects of Epanova and Lovaza on Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA) After Low-fat Meals
AstraZeneca
NCT01431690
The Effect of Multiple Doses of Epanova® on the Multiple-Dose Pharmacokinetics of Simvastatin in Healthy Normal Subjects
AstraZeneca
NCT01486433
Predictors of Response to Fenofibrate
University of Alabama at Birmingham
NCT01023750
Boosted Lexiva With Lovaza Adjunctive Therapy in Hypertriglyceridemic, HIV-Infected Subjects
Felizarta, Franco, M.D.
NCT01010399
PK Study Comparing Metformin Eicosapentaenoate to a Combined Dose of Metformin Hydrochloride and Ethyl Ester EPA
Thetis Pharmaceuticals
NCT02113163
Niacin for Treatment of Elevated Cholesterol and Triglycerides in HIV-Infected Patients
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00046267
Vascular and Lipid Effects of Omega-3 Fatty Acids in People With Moderately Elevated Triglycerides
Penn State University
NCT00504309
Effect of Maraviroc on Metabolic Function in Obese Subjects (Phase I)
Washington University School of Medicine
NCT01133210
Effects of Diet Interventions on Monocytes in Metabolic Syndrome
Baylor College of Medicine
NCT03591588
Changes in Lipids and Safety of Raltegravir in HIV+ Patients With Hyperlipidemia While on Current Standard Therapy
The Miriam Hospital
NCT00887653
Pilot Study To Assess CAT-2003 in Patients With Severe Hypertriglyceridemia
Catabasis Pharmaceuticals
NCT01968720
Study of Gemcabene in Adults With FPLD
Elif Oral
NCT03508687
Novel Therapies for Metabolic Complications of Lipodystrophies
University of Texas Southwestern Medical Center
NCT00457938
Regulation of Sterol Homeostasis
US Department of Veterans Affairs
NCT00018720
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 8 |
| Phase 2 | 5 |
| Phase 3 | 5 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Hypertriglyceridemia records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Hypertriglyceridemia trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Hypertriglyceridemia page
27 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Hypertriglyceridemia trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- AstraZeneca sponsors the most Hypertriglyceridemia trials on record, review their full trial history before evaluating a specific study. See AstraZeneca's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Hypertriglyceridemia condition card totals 27 registered trials; most-linked intervention Placebo; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.